Promising combo for tough breast cancers hits early hurdle
NCT ID NCT03101748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of targeted drugs (neratinib, pertuzumab, trastuzumab) and chemotherapy (paclitaxel, doxorubicin, cyclophosphamide) in 34 people with advanced or inflammatory breast cancer. The goal was to find the best dose and see if the combo could shrink tumors before surgery. However, the study was terminated early, so we have limited data on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- neratinib, pertuzumab, trastuzumab, paclitaxel, doxorubicin, cyclophosphamide
- What this could lead to
- If successful, this combination could offer a new treatment option for aggressive breast cancers that are hard to treat.
- What could go wrong
- The trial was terminated early, so results are limited. It is a small, early-phase study, and the drug combination may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST INFLAMMATORY CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?